Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: The truth in the end!

Neurogastroenterology and Motility

Volumn 24, Issue 8, 2012, Pages 697-704

  Scarpignato, C ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Acid suppression; Gastro esophageal reflux disease; Non erosive reflux disease; Potassium competitive acid blockers; Proton pump inhibitors; Refractory gastro esophageal reflux disease

Indexed keywords

AGN 201904Z; BENATOPRAZOLE; E 3710; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYALURONIC ACID; ILAPRAZOLE; LANSOPRAZOLE; LINAPRAZAN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; REVAPRAZAN; RQ 4; TAK 438; UNCLASSIFIED DRUG; YH 4808;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DRUG EFFICACY; DRUG TREATMENT FAILURE; ESOPHAGOSCOPY; FUNCTION TEST; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; NON EROSIVE REFLUX DISEASE; PALLIATIVE THERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE;

BARRETT ESOPHAGUS; ESOPHAGITIS, PEPTIC; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS;

EID: 84863825969     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2012.01977.x     Document Type: Article

References (60)

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
2. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710-7.
3. Vakil N. Disease definition, clinical manifestations, epidemiology and natural history of GERD. Best Pract Res Clin Gastroenterol 2010; 24: 759-64.
4. Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2010; 32: 1222-7.
5. Vial M, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res 2010; 182: 1-17.
6. Cadiot G, Sekera E, Mignon M. Gastric secretion in gastroesophageal reflux disease. Front Gastrointest Res 1994; 22: 209-22.
7. Scarpignato C, Pelosini I, Contini S. How abnormal is gastric function in patients with Barrett's esophagus? In: Giuli R, Siewert JR, Couturier D, Scarpignato C, eds. Barrett's Esophagus. 250 Questions, 250 Answers. Volume 1. Paris: John Libbey Eurotext, 2003: 26-34.
8. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-18100.
9. 2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease (Cochrane Review). Cochrane Database Syst Rev 2010; 11: CD002095.
10. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety. Pharmacol Res 2009; 59: 135-53.
11. Tack J, Fass R. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther 2004; 19(Suppl. 1): 28-34.
12. Katz PO, Scheiman JM, Barkun AN. Review article: acid-related disease - what are the unmet clinical needs? Aliment Pharmacol Ther 2006; 23(Suppl. 2): S9-22.
13. Modlin IM, Hunt RH, Malfertheiner P et al. Diagnosis and management of non-erosive reflux disease - the Vevey NERD Consensus Group. Digestion 2009; 80: 74-88.
14. Dean BB, Gano AD, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-64.
15. Gupta N, Inadomi JM, Sharma P. Perception about gastroesophageal reflux disease (GERD) and its impact on daily life in the general population: results from a large population based AGA survey. Gastroenterology 2012; 142(Suppl. 1): S411.
16. Yuan Y, Hunt RH. Evolving issues in the management of reflux disease? Curr Opin Gastroenterol 2009; 25: 342-51.
17. Vela MF. Empiric PPI therapy or endoscopy for the initial management of patients with GERD in the absence of alarm features? Nat Clin Pract Gastroenterol Hepatol 2008; 5: 548-9.
18. Tytgat GN. Are there unmet needs in acid suppression? Best Pract Res Clin Gastroenterol 2004; 18(Suppl): 67-72.
19. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 23: 1473-7.
20. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol 2005; 100: 1237-42.
21. Chey WD, Mody R, Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci 2010; 55: 3415-22.
22. Chey WD, Mody R, Chen L et al. Nighttime symptoms and sleep impairment among patients with gastro-esophageal reflux disease (GERD) receiving prescription (Rx) proton pump inhibitors (PPIs). Gastroenterology 2008; 134(Suppl. 1): A323-4.
23. Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol 2010; 24: 923-36.
24. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83: 66-8.
25. Reddymasu SC, Sharma P. Advances in endoscopic imaging of the esophagus. Gastroenterol Clin North Am 2008; 37: 763-74.
26. Zentilin P, Savarino V, Mastracci L et al. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol 2005; 100: 2299-306.
27. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17: 537-45.
28. Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995; 37: 457-64.
29. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58: 295-309.
30. Tsoukali E, Sifrim D. The role of weakly acidic reflux in proton pump inhibitor failure, has dust settled? J Neurogastroenterol Motil 2010; 16: 258-64.
31. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut 2008; 57: 674-83.
32. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004; 53: 1024-31.
33. Zerbib F, Roman S, Ropert A et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101: 1956-63.
34. Mainie I, Tutuian R, Shay S et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55: 1398-402.
35. Savarino E, Zentilin P, Tutuian R et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008; 103: 2685-93.
36. Fass R, Ofman JJ. Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 1901-9.
37. Savarino E, Marabotto E, Zentilin P et al. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig Liver Dis 2011; 43: 542-7.
38. Galmiche JP, Clouse RE, Bálint A et al. Functional esophageal disorders. Gastroenterology 2006; 130: 1459-65.
39. Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil 2012; 24: 747-e350.
40. Hungin AP, Hill C, Molloy-Bland M, Raghunath A. Systematic review: patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012; 10: 109-16.
41. Karamanolis G, Vanuytsel T, Sifrim D et al. Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008; 53: 2387-93.
42. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120: 1599-606.
43. Zerbib F, Duriez A, Roman S, Capdepont M, Mion F. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008; 57: 156-60.
44. Smith JL, Opekun AR, Larkai E, Graham DY. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 1989; 96: 683-9.
45. Hunt R. Acid suppression for reflux disease: 'off-the-peg' or a tailored approach? Clin Gastroenterol Hepatol 2012; 10: 210-3.
46. Johnson LF, Demeester TR. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974; 62: 325-32.
47. Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: where do we go from here? Dig Dis 2006; 24: 11-46.
48. Kahrilas PJ, Shaheen NJ, Vaezi MF et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383-91.
49. Yuhan Y, Hunt RH. Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? Am J Gastroenterol 2008; 103(Suppl. 1): S50.
50. Clayton SB, Rife CC, Singh ER, Kalbfleisch JH, Castell DO. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing. Dis Esophagus 2012;doi: .
51. Boeckxstaens GE, Denison H, Jensen JM, Lehmann A, Ruth M. Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'. Curr Opin Pharmacol 2011; 11: 630-3.
52. Attwood SE, Galmiche JP. A debate on the roles of antireflux surgery and long term acid suppression in the management of gastro-oesophageal reflux disease. Frontline Gastroenterol 2011; 2: 206-11.
53. Scarpignato C, Hunt RH. Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr Opin Pharmacol 2008; 8: 677-84.
54. Fass R, Inadomi J, Han C, Mody R, O'Neil J, Perez MC. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol 2012; 10: 247-53.
55. Hunt RH, Armstrong D, Yaghoobi M et al. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008; 28: 187-99.
56. Hunt RH, Armstrong D, Yaghoobi M, James C. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30mg, 60mg and 90mg vs. esomeprazole 40mg in healthy male subjects. Aliment Pharmacol Ther 2010; 31: 648-57.
57. Kahrilas PJ, Dent J, Lauritsen K et al. Arandomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5: 1385-91.
58. Dent J, Kahrilas PJ, Hatlebakk J et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008; 103: 20-6.
59. +-competitive acid pump antagonist exhibits more potent, sustained inhibition of gastric acid secretion with faster onset of action. Gut 2011; 60(Suppl. 3): A268.
60. Tajimi M, Nii T, Takahashi N, Yamamoto T, Koizumi S. First-in-human study of the novel acid pump antagonist, RQ-00000004, demonstrated a rapid elevation of gastric pH following single oral administration in healthy subjects. Gastroenterology 2011; 140(Suppl. 1): S80.